Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study

Immune checkpoint inhibitors combined with antiangiogenic therapy reportedly have potential synergistic antitumor activity. We investigated the activity and safety of this regimen for recurrent/metastatic nasopharyngeal carcinoma (NPC). METHODS: This single-arm, Simon two-stage study enrolled patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Xi, Zhang, Wei-Jing, You, Rui, Zou, Xiong, Wang, Zhi-Qiang, Ouyang, Yan-Feng, Peng, Lan, Liu, You-Ping, Duan, Chong-Yang, Yang, Qi, Lin, Chao, Xie, Yu-Long, Chen, Si-Yuan, Liu, Yong-Long, Gu, Chen-Mei, Xie, Ruo-Qi, Huang, Pei-Yu, Hong, Ming-Huang, Hua, Yi-Jun, Chen, Ming-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414735/
https://www.ncbi.nlm.nih.gov/pubmed/36735896
http://dx.doi.org/10.1200/JCO.22.01450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414735/
https://www.ncbi.nlm.nih.gov/pubmed/36735896
http://dx.doi.org/10.1200/JCO.22.01450

Ejemplares similares